This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Sector Weekly Rewind

BOSTON ( TheStreet) -- Adam Feuerstein's take on the biotech week that ended Nov. 12, 2010:

The week's best-performing stocks in the sector: Aastrom Biosciences (ASTM) (+48%), AspenBio Pharma (APPY - Get Report) (+32%), Bionovo (BNVO) (28%), Vermillion (VRML) (+26%) and Genomic Health (GHDX) (+20%).

Is it any coincidence that Aastrom filed a $75 million mixed shelf registration Friday?

Human Genome Sciences (HGSI): FDA Reviews Lupus Drug

The week's worst-performing stocks: Surmodics (SRDX - Get Report) (-30%), Epicept (EPCT) (-28%), Metabolix (MBLX) (-25%), Angiotech Pharmaceuticals (ANPI) (-21%) and Repros Therapeutics (RPRXD) (-19%).

Cadence Pharmaceuticals (CADX) sold 11.5 million shares at $8, raising $86 million to fund commercial launch of Ofirmev, a hospital-based intravenous form of acetameniphan.

> > Bull or Bear? Vote in Our Poll

Athersys (ATHX - Get Report) received FDA clearance to start phase II study of Multistem stem cell therapy for inflammatory bowel disease.

Arena Pharma (ARNA): 'Marginal' Obesity Drug Now Unsafe?

Research abstracts for American Society of Hematology annual meeting were posted online.

Cerus (CERS) priced 7.37 million stock units (stock and warrants) at $2.85 a unit, raising $20 million.

FDA cleared Polymedix (PYMX.OB) to begin human clinical trials of antibiotic PMX-30063.

Osiris Therapeutics (OSIR) Drags Feet on U.S. Approval Filing

Dendreon (DNDN) filed for FDA approval of an expansion to its Provenge manufacturing plant in New Jersey, while the Centers for Medicare and Medicaid (CMS) released the technical assessment of Dendreon's Provenge ahead of next week's National Coverage Determination meeting.

Micromet (MITI) sold 9.9 million shares at $7.30, raising $72 million.

This week's Biotech Stock Mailbag: Theratechnologies (TH.TO), Arena Pharmaceuticals, Amarin (AMRN), and Osiris Therapeutics.

A preview of next week's important regulatory meetings facing Human Genome Sciences, Dendreon and MELA Sciences (MELA).

Human Genome: Benlysta FDA Panel Preview

Glaxo (GSK) Lawyer Indicted for Obstructing the FDA (via Pharmalot)

European Drug Approval Agency Looking for new leader (via invivo blog)

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:
Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
APPY $3.09 3.00%
ATHX $2.30 2.20%
ASTM $3.10 -0.18%
DNDN $0.06 -6.02%
SRDX $20.14 -1.80%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs